FDA approves new drug Keytruda for advanced skin cancer

The U.S. Food and Drug Administration (FDA) has approved a new drug called Keytruda (pembrolizumab) for treating advanced melanoma, a serious form of skin cancer. It is specifically for patients whose melanoma cannot be removed by surgery or has spread to other parts of the body. This approval also includes its use for some patients after surgery to help prevent the cancer from returning. Keytruda works by helping the body's own immune system fight the cancer cells, representing a different approach from many other cancer treatments. This approval is significant because advanced melanoma has been very difficult to treat, and it offers a new option for patients and their doctors. It marks the arrival of a new type of treatment, called immunotherapy, for this disease. It's important to remember that every patient's situation is unique. This approval means the drug is now available as a treatment choice, but it does not mean it is the right choice for everyone. The most important step for anyone considering this treatment is to have a detailed conversation with their own doctor. Doctors can help explain the potential benefits and risks based on a patient's specific health and type of cancer.